The history and mystery of sacubitril/valsartan: From clinical trial to the real world

The history and mystery of sacubitril/valsartan: From clinical trial to the real world

Heart failure is a serious threat to human health, with morbidity and mortality rates increasing despite the existence of multiple treatment options. Therefore, it is necessary to identify new therapeutic targets for this disease. Sacubitril/valsartan is a supramolecular sodium salt complex of the e...

Full description

Bibliographic Details
Main Authors:	Mingsong Zhang, Yifei Zou, Yangxue Li, He Wang, Wei Sun, Bin Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	heart failure sacubitril/valsartan cardiovascular clinical application basic medical research
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1102521/full

Similar Items

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Sacubitril/valsartan in Heart Failure and Beyond—From Molecular Mechanisms to Clinical Relevance
by: Maja Nikolic, et al.
Published: (2022-06-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Sacubitril/Valsartan for Heart Failure: Exciting Times but Are Doctors Informed and Ready?
by: Prithwish Banerjee
Published: (2017-01-01)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy
by: Vanesa Gregorietti, et al.
Published: (2020-11-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
by: Hongzhou Zhang, et al.
Published: (2020-12-01)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
by: Ana Martín‐Garcia, et al.
Published: (2020-04-01)

Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data
by: Maria Klara Frey, et al.
Published: (2021-10-01)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
by: Chen Wang, et al.
Published: (2023-06-01)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
by: Po‐Cheng Chang, et al.
Published: (2020-10-01)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
by: Swathi Pathadka, et al.
Published: (2021-01-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Sharath Kommu, et al.
Published: (2024-03-01)

Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out‐of‐Pocket Costs
by: Birju R. Rao, et al.
Published: (2023-04-01)

Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure
by: Diana-Carina Iovanovici, et al.
Published: (2022-09-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
by: Amr Abdin, et al.
Published: (2022-12-01)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
by: Valeria Visco, et al.
Published: (2022-10-01)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
by: Ulrik Ø Andersen, et al.
Published: (2020-05-01)

Sacubitril/valsartan for heart failure in patients with complex adult congenital heart disease – Experience from a tertiary centre in Singapore
by: Limin Yan, et al.
Published: (2021-12-01)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
by: Alex Heyse, et al.
Published: (2019-12-01)

Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up
by: Carla Paolini, et al.
Published: (2021-08-01)

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
by: Zakiyah N, et al.
Published: (2021-10-01)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
by: Vilela-Martin JF
Published: (2016-05-01)

Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF
by: Massimo Iacoviello, et al.
Published: (2024-02-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
by: Juan Carlos López‐Azor, et al.
Published: (2019-12-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
by: Jawad H. Butt, et al.
Published: (2024-02-01)

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
by: Juan Jiang, et al.
Published: (2023-03-01)